Some patients prefer injection speed and potency
C.HalliwellB
Ensuring equitable access to these effective but high-cost medications, as well as supporting individuals so that they can stay on the therapy long-term, should be a priority for our clinicians and policymakers. Semaglutide, which is approved for managing diabetes, obesity and preventing recurrent cardiovascular events, is already the nations top-selling drug by pharmaceutical spending
These fast-dissolving tablets provide an alternative option for individuals who prefer not to use injections
This is more likely in patients with risk factors such as kidney problems, sepsis, or malnutrition
The decision to continue, modify, or discontinue Ozempic should be made collaboratively, weighing the therapeutic benefits against the impact of adverse effects on quality of life